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The protein prenylation is one of the essential post-translational protein modifications, which extensively exists in the eukar-
yocyte. It includes protein farnesylation and geranylgeranylation, using farnesyl pyrophosphate (FPP) or geranylgeranyl pyro-
phosphate (GGPP) as the substrate, respectively. The prenylation occurs by covalent addition of these two types of isoprenoids 
to cysteine residues at or near the carboxyl terminus of the proteins that possess CaaX motif, such as Ras small GTPase family. 
The attachment of hydrophobic prenyl groups can anchor the proteins to intracellular membranes and trigger downstream cell 
signaling pathway. Geranylgeranyl biphosphate synthase (GGPPS) catalyzes the synthesis of 20-carbon GGPP from 15-carbon 
FPP. The abnormal expression of this enzyme will affect the relative content of FPP and GGPP, and thus disrupts the balance 
between protein farnesylation and geranylgeranylation, which participates into various aspects of cellular physiology and pa-
thology. In this paper, we mainly review the property of this important protein post-translational modification and research 
progress in its regulation of cigarette smoke induced pulmonary disease, adipocyte insulin sensitivity, the inflammation re-
sponse of Sertoli cells, the hepatic lipogenesis and the cardiac hypertrophy. 
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The post-translational lipid modification of proteins has 
been recognized as a key process for the regulation of pro-
tein localization and physiological function. The protein 
prenylation is one of the most important modifications crit-
ical for the membrane association of a plethora of signaling 
proteins with fundamental roles in cell biology, including 
cell growth, differentiation, proliferation and protein traf-
ficking [1]. The two types of isoprenoids, farnesyl pyro-
phosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), 
are synthesized by the cellular mevalonate pathway. Protein 
prenylation occurs by the addition of them to a cysteine 
residue located at or near the carboxyl terminal end of the 
protein [2]. A series of signaling pathway will be altered 
once this modification is disrupted, which accounts for the 
pathological progression of many diseases including neuro-
degenerative disorders and cancers. 
1  The sources of FPP and GGPP 
The isoprenoids are all derived from the common five-  
carbon (C5) building unit isopentenyl diphosphate (IPP) and 
its isomer dimethylallyl diphosphate (DMAPP). The head- 
to-tail or head-to-head addition of C5 units forms the build-
ing blocks of the tens of thousands of more complex iso-
prenoids [3]. Isoprenoids are synthesized exclusively 
through the mevalonate (MVA) pathway in animals, fungi 
and archaebacteria. Besides, plants and microbes can also 
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use 2-C-methyl-D-erythritol-4-phosphate (MEP) pathway 
for isoprenoid synthesis [1,4,5]. In the MVA pathway, 
firstly acetyl-CoA is converted to 3-hydroxy-3-methylglu- 
taryl coenzyme A (HMG-CoA) by HMG-CoA synthase, 
and then to mevalonate by HMG-CoA reductase. Subse-
quently, the FPP, which is synthesized from IPP by FPP 
synthase (FPPS), can be converted through four different 
pathways via a number of enzyme steps. One is to synthe-
size GGPP by GGPP synthase (GGPPS). One is to farnesyl-
ate the proteins containing CaaX motif by farnesyltransfer-
ase (FTase). The other is to produce cholesterol by a series 
of processes. Additionally, FPP can also be used to synthe-
size Heme A and dolichol, etc. GGPP, which is derived 
directly from FPP, can make the proteins containing   
CaaX motif geranylgeranylated by geranylgeranyltransfer-
ase (GGTase) and be also used to synthesize ubiquinone 
(Figure 1). 
2  Protein prenylation 
Protein prenylation, which occurs shortly after translation, 
is irreversible during the lifetime of the protein [2]. It con-
tains protein farnesylation and geranylgeranylation that is 
catalyzed by FTase or GGTase (GGTase I and II), respec-
tively. FTase and GGTase I are both heterodimers and con-
sist of two subunits, α and β. The α subunit is encoded by 
the same gene, FNTA. The β subunit is encoded by FNTB 
and PGGTIB respectively [6]. Both of these two transferas-
es recognize proteins that possess a CaaX motif at their 
C-terminal end, where C is the cysteine that becomes 
prenylated, a is an aliphatic amino acid and X is any other 
residue. The nature of the X residue determines whether a 
protein will be farnesylated or geranylgeranylated. Proteins  
 
 
Figure 1 (color online)  The mevalonate pathway. Mevalonate is the 
precursor of FPP and GGPP, which are the substrate for prenylation en-
zymes. In addition to prenylation, FPP can produce cholesterol, Heme A 
and dolichol via a series of steps. GGPP can synthesize ubiquinone. The 
specific inhibitors targeting corresponding enzymes are indicated in grey 
font. 
ending in serine, methionine, alanine or glutamine become 
farnesylated, while proteins ending in leucine or isoleucine 
become geranylgeranylated [2,7]. However, there are a few 
exceptions that proteins can alternatively undergo either 
type of modification. When X is phenylalanine, the proteins 
can be either farnesylated or geranylgeranylated [8]. The 
alternative prenylation can occur under situations of limited 
isoprenoid availability. For example, K-Ras can be 
geranylgeranylated in cells treated with farnesyltransferase 
inhibitors (FTIs) [9]. 
The typical substrates that are farnesylated by FTase in-
clude many members of Ras superfamily of small GTPases 
(H-Ras, K-Ras, N-Ras, Ras2, Rap2, RhoB, RhoE, Rheb, 
TC10, TC21), as well as the nuclear lamina proteins lamin 
A and B, the kinetochore proteins CENP-E and CENP-F, 
cGMP phosphodiesterase α, γ subunit variants of G proteins, 
DnaJ heat-shock protein homologs, rhodopsin kinase, the 
peroxisomal membrane proteins Pex19 and PxF and so on. 
GGTase I preferentially geranylgeranylates some of the 
other small GTPases (Rac1, Rac2, RalA, Rap1B, RhoA, 
RhoB, RhoC, Cdc42, Rab8, Rab11, Rab13), as well as some 
γ subunit variants of G proteins, cGMP phosphodiesterase β 
and the plant calmodulin CaM53 [6]. GGTase II, also called 
Rab geranylgeranyltransferase, transfers one or two mole-
cules of geranylgeranyl to Rab family which contains CC, 
CAC, CCX or CCXX motifs. The prenylation by GGTase II 
requires the participation of the Rab escort protein (REP), 
an auxiliary protein involved in the recognition of Rab by 
GGTase II [2]. 
The largest families of prenylated proteins are the intra-
cellular GTP-binding proteins involved in signaling trans-
duction. Protein prenylation is essential for their GDP/GTP 
binding changes and GTPase activity happening on the cell 
membrane because it directly makes the proteins associated 
with membrane compartments [1]. Either a farnesyl or a 
geranylgeranyl group attachment to a cysteine at or near the 
C-terminal end is through a thioether linkage (-C-S-C-), 
following further post-prenylation processing. Briefly, the 
three C-terminal amino acids (aaX) are then cleaved by the 
endoprotease Rce-1, and the remaining C-terminal prenyl-
ated cysteine residue is carboxymethylated by an 
S-adenosylmethione (SAM)-dependent protein carboxy- 
methylase [2]. This group of modifications increases the 
hydrophobicity of the protein and facilitates its interaction 
with membranes (Figure 2). 
3  Protein prenylation and diseases 
Given the ubiquitous nature of the protein prenylation and 
its roles in cellular biology, defects in isoprenoid biosynthe-
sis or regulation can cause lots of diseases, such as cancer, 
cardiovascular diseases, neurodegenerative disorders and 
metabolic diseases. The abnormal expression or even activ-
ity of enzymes involved in the MVA pathway can lead to 
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Figure 2 (color online)  The post-prenylation processing. Following prenylation, the prenylated protein protease removes the three C-terminal amino acids 
(aaX), and the remaining cysteine residue is carboxymethylated by a specific methyltransferase. This methylation is reversible due to its esterase activity. 
The modification increases the hydrophobicity of the protein and facilitates its interaction with membranes. SAM, S-adenosyl-methionine; SAH, 
S-adenosyl-homocysteine. 
impaired protein prenylation. Mutations within the Ras 
family could be identified in as many as 10%15% of all 
human cancers. Rational therapies that target the Ras 
prenylation by genetic methods and pharmacological inter-
vention may repress Ras-mediated malignant transformation 
[10]. FTIs and GGTIs have been recently developed as po-
tential anticancer drugs because of their inhibition on Ras 
and Rho family respectively [7]. The research by Mijimolle 
utilizing FTase β subunit knockout mouse has provided that 
farnesylated proteins are not required for the initial malig-
nant cellular transformation but are critical for tumor pro-
gression and maintenance [11]. It is also reported that abla-
tion of GGTase I β subunit could inhibit K-Ras induced 
lung tumour formation [12], but activate inflammatory re-
sponse in macrophages through Rho signaling [13]. Muta-
tions in the GGTase II gene caused Hermansky-Pudlak 
syndrome, characterized by disorders of pigmentation, pro-
longed bleeding, and ceroid deposition, often accompanied 
by severe fibrotic lung disease and colitis [14]. On the other 
hand, mutations in REP-1 could lead to retinal degeneration 
associated with a defect in the prenylation of Rab27a 
[15,16]. It is suggested that GGPP stimulated PPARγ ex-
pression and adipogenesis and thus inhibited osteoblast 
mineralization and differentiation [17]. Direct inhibition of 
GGPPS by digeranyl bisphosphonate (DGBP) resulted in 
depletion of GGPP and impaired protein geranylgeranyla-
tion in MC3T3-E1 preosteoblast cells but accumulated FPP 
level. Therefore, DGBP treatment did not lead to increased 
osteoblast differentiation [18]. 
3.1  The Ras prenylation- and cigarette smoke-induced 
pulmonary disease 
The long-term stress of low intensity stimulation by the 
hazardous materials is the cause of some chronic diseases, 
for instance, long-term cigarette smoke stimulation leads to 
the COPD (chronic obstructive pulmonary disease), eventu-
ally the loss of function of pulmonary. Cigarette smoke is 
the reason for 80%90% of patients with COPD, neverthe-
less only 10%15% of smokers exhibit obviously clinical 
obstructive pulmonary. Thus the variation of individual 
genes expression leads to the different response to cigarette 
smoke. In addition, the mechanism by which long-term 
stimulation of cigarette smoke leads to severe clinical dis-
eases is still unknown. In our previous study, cigarette 
smoke induced the early growth response gene (Egr-1) ex-
pression through MAPK signaling and regulated the metal-
loprotease activity and the inflammation in pulmonary 
[1921]. We revealed that Egr-1 could bind to the promoter 
of GGPPS gene in a cigarette smoke dependent way 
through ChIP and identified GGPPS as one of the target 
genes of Egr-1 [22]. Furthermore, both Egr-1 and its target 
genes GGPPS and HO-1 were increasingly expressed in the 
lung from the cigarette smoke induced COPD mice. GGPPS 
is the enzyme that prenylates and activates Ras and 
re-activates the MAPK/Erk1/2, sequentially activates Egr-1 
expression in a positive feedback way [23,24]. The constant 
activated Egr-1 by long-term smoke enhances the inflam-
mation in pulmonary and over-activates the metalloprotease, 
eventually aggravates the impairment of lung tissue. To-
gether, we declared that the activity of Egr-1/GGPPS/Ras 
pathway is highly relevant to cigarette smoke-induced pul-
monary diseases. 
3.2  Protein prenylation and insulin resistance 
Obesity is the primary cause of insulin resistance [25]. 
GGPPS is highly expressed in the liver, muscle and adipose 
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tissue from ob/ob mice with extreme insulin resistance and 
hyperinsulinemia [26]. It is also reported that insulin can 
activate the geranylgeranyl transferase and induce Rab 
geranylgeranylated in 3T3-L1 preadipocytes. Inhibiting the 
geranylgeranyl transferase activity can down-regulate the 
phosphorylation of MAPK pathway without affecting the 
PI3K/AKT pathway in 3T3-L1 preadipocytes [27]. 
In our study, the positive feedback way of MAPK/Egr-1/ 
GGPPS/Ras also exerts a primary role in other stress such 
as hyperinsulinism of type 2 diabetes. In this case, insulin 
can trigger both the opposite pathway: PI3K/AKT and 
MAPK. PI3K/AKT promotes the glucose uptake that is the 
positive function of insulin while MAPK can induce insulin 
resistance by activating gene expression that is the negative 
function of insulin. We found that the long-term insulin 
stimulation turned the transient elevation of Egr-1 constant-
ly expressed so as to make GGPPS constantly activated. 
GGPPS further activated K-Ras by enhancing its geranyl-
geranylation and constantly activated the Ras/MAPK/Erk1/2 
signaling which could phosphorylate IRS-1 at Ser612, 
eventually inhibited the insulin signaling and promoted the 
insulin resistance [28]. Furthermore, Egr-1 could activate 
both the PI3K/AKT and MAPK pathway. Egr-1 
dephosphorylated PIP3 to PIP2 and inhibited the activation 
of AKT by PI3K through PTEN. The highly expressed 
Egr-1 in adipose tissue not only led to adipose insulin re-
sistance but also enhanced the inflammation cytokines se-
cretion such as TNF-α and IL-6, finally inhibited the sys-
temic insulin sensitivity. Over-expression of Egr-1 in adi-
pose tissue in mice could result in systemic insulin re-
sistance while loss of function of adipocytes Egr-1 could 
improve the insulin sensitivity in db/db mice [29]. Taken 
together, our study revealed that Egr-1, as an important reg- 
ulator, could simultaneously regulate both PI3K/AKT and 
MAPK signaling pathway (Figure 3). This makes Egr-1 a 
new potential pharmaceutical target for insulin resistance.  
3.3  The Ras prenylation and male infertility 
Mumps commonly affects children 59 year of age, and can 
lead to permanent adult sterility in certain cases. Mumps 
infection results in proliferation of macrophages and pro-
gressive degeneration of the seminiferous tubules, exhibit-
ing a significant spermatogonia loss and occasionally, Ser-
toli cell-only syndrome [3032]. A physical barrier, the 
so-called blood-testis barrier (BTB), forms between Sertoli 
cells and allows for these cells to control and regulate the 
environment of the developing germ cells. More important-
ly, in addition to the BTB, Sertoli cells can secrete im-
munomodulatory factors that create an effectively im-
mune-privileged environment [33,34]. 
We observed that GGPPS expression in the testis of in-
fertile patients with a history of mumps infection was sig-
nificantly lower compared with that in noninfected infertile 
patients, because of the enhanced methylation level of the 
GGPPS promoter after mumps infection. Given that GGPPS 
was primarily observed in the cytoplasm of Sertoli cells and 
spermatogonia, and Sertoli cells played a central role in the 
regulation of immune privilege during adulthood, we hy-
pothesized that GGPPS regulated protein prenylation in 
Sertoli cells was crucial for virus infection. To further study 
the function of GGPPS in immune response, we constructed 
Sertoli cell-specific GGPPS knockout mice. The Sc- 
GGPPS mice exhibited adult infertility. Surprisingly, 
although the GGPPS gene was deleted in Sertoli cells rather 
than in spermatogonia, the number of Sertoli cells in testic-  
 
 
Figure 3 (color online)  GGPPS regulates insulin sensitivity in adipocyte [28]. Egr-1 is greatly increased in hyperinsulinism and in insulin resistance 
through activation of the Erk1/2 MAPK pathway. The highly expressed Egr-1 can reactivate Erk1/2 by triggering GGPPS transcription and promoting Ras 
membrane association. The sustained activation of Erk1/2 can phosphorylate IRS-1 on Ser612 and inhibit its activity. 
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ular tubules was unaltered, whereas the number of sper-
matogonia was significantly decreased at postnatal 5d. Be-
cause there is no BTB between Sertoli cells until 3 weeks, 
the spermatogonia loss at this stage was induced by in-
creased cytokines and chemokines release and seminiferous 
tubule macrophage invasion. Further analysis showed that 
GGPPS deletion in Sertoli cells increased H-Ras farnesyla-
tion and constitutively activated MAPK Erk1/2, which was 
responsible for NF-κB activation and inflammatory reaction, 
and thus for the augmentation of cytokines (IL-6, TNF-α) 
and chemokines (G-CSF, CCL2 (MCP-1), CCL3 (MIP-1α), 
CXCL2 (MIP-2α)). These inflammatory factors then bound 
to the receptors on spermatogonia and activated cell apop-
tosis signaling pathway, leading to a long-term effect on 
adult infertility [35,36]. Macrophages could be recruited by 
chemokines, easily invade the testicular tubules and attack 
developing spermatogonium cells, resulting in spermatogo-
nia apoptosis [37]. 
Our results indicated that protein prenylation in Sertoli 
cells was critical for regulating the immune response in tes-
tis before puberty (Figure 4). Our data provided a novel 
mechanism by which mumps infection during childhood 
results in adult sterility. 
3.4  Protein prenylation and nonalcoholic fatty liver 
disease 
Non-alcoholic fatty liver disease (NAFLD) represents a 
histological spectrum of liver disease characterized by ex-
cess fat accumulation in the liver without a history of alco-
hol abuse [38]. As economy grows and the life style chang-
es, NAFL increased gradually and has emerged as one of 
the most prevalent chronic liver disease in the past few 
decades. The incidence of NAFL is about 20% in Chinese 
but reaches as high as 75% in obese people [39]. It ranges 
from simple steatosis (hepatic steatosis, non-alcoholic fatty 
liver, NAFL) to non-alcoholic steatohepatitis (NASH), ad-
vanced liver fibrosis, cirrhosis and ultimate hepatocellular 
carcinoma (HCC) [40,41]. Extensive research and clinical 
studies have been performed to investigate the pathogenesis 
of NALFD, although the precise cellular networks are still 
not fully elucidated. 
Simple steatosis can be reversed. Therefore, understand-
ing the mechanism of TG accumulation would help to iden-
tify therapeutic interventions for hepatic steatosis. Our re-
search demonstrated that GGPPS was up-regulated in the 
liver of obesity-associated hepatic steatosis mice models. 
Cellular over-expression of GGPPS resulted in massive TG 
accumulation in primary hepatocytes, and elevated lipid 
droplets marker genes as ADRP, Perlipin, aP2 and C/EBPα. 
To explore the function of GGPPS in hepatic lipid homeo-
stasis, we established liver-specific GGPPS knockout mice 
that fed with regular chow and high-fat diet (HFD). Mice 
with liver-specific GGPPS deletion were protected from 
HFD-induced hepatic steatosis. Further investigation re-
vealed that GGPPS deficiency altered the ratio of FPP to 
GGPP. The accumulated FPP resulted in the inhibition on 
de novo lipogenesis (DNL) in hepatocytes, on one hand,  
 
 
Figure 4 (color online)  Mumps infection during childhood results in adult sterility through altered protein prenylation in Sertoli cells. The expression of 
GGPPS was decreased due to elevated promoter methylation in the testes of infertile patients with mumps infection history. GGPPS deletion in mouse Ser-
toli cells enhanced H-Ras farnesylation and constitutively activated MAPK Erk1/2, which was responsible for NF-κB activation and inflammatory reaction, 
and thus for the augmentation of cytokines and chemokines. These inflammatory factors then bound to the receptors on spermatogonia. Macrophages could 
be recruited by chemokines, easily invade the testicular tubules and attack developing spermatogonium cells. These result in spermatogonia apoptosis, lead-
ing to a long-term effect on adult infertility. 
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through activating FXR/SHP signaling which in turn sup-
pressed SREBP-1 expression and processing, and LXR ac-
tivation, as reported elsewhere [42]; on the other hand, the 
inhibition is through promoting the LKB1/AMPK signaling 
(unpublished data). All in all, GGPPS is a key regulator of 
lipid metabolism in the liver. Specific targeting GGPPS in 
the liver may provide a valuable therapeutic strategy for 
hepatic steatosis. 
3.5  Protein prenylation and cardiac hypertrophy 
Growing evidence has suggested that small GTPases family 
(including Ras and Rho) and heterotrimeric G proteins are 
activated by a variety of extracellular ligands, such as angi-
otension II, endothelin-1, phenylephrine, as well as me-
chanical forces, which can lead to cardiac hypertrophy me-
diated by GPCR [4345]. Hypercholesterolemia is a key 
cause for atherosclerosis and associated cardiovascular pa-
thologies, including thrombosis and infarction. Statins, the 
HMG-CoA reductase inhibitors, often have beneficial ef-
fects on these symptoms by efficiently lowering cholesterol 
and the prenylation of RhoA in either clinical trials or ani-
mal models research [46]. Genetic disruption of Rce-1 in 
mice led to a dilated cardiomyopathy [47]. Furthermore, 
cardiac-specific overexpression of FPPS induced cardiac 
hypertrophy and dysfunction through RhoA hyperactivation 
[48]. Chronic inhibition of FPPS attenuated cardiac hyper-
trophy in spontaneously hypertensive rats [49]. Early in 
2006, Olson’s group has indicated that the enzymes in-
volved in the mevalonate pathway, including HMG-CoA 
reductase and GGPPS, controlled the heart formation in 
Drosophila [50]. From the above research, we proposed that 
there might be a balance between protein geranylgeranyla-
tion and farnesylation that is required for heart function 
maintenance. 
GGPPS, which is a branch point enzyme in the mevalo-
nate metabolic pathway, can utilize FPP to synthesize  
GGPP. Previous studies have suggested that treatment with 
DGBP could accumulate the level of FPP and increase pro-
tein farnesylation [18]. Therefore, we thought that GGPPS 
might be important for heart function as a critical switch to 
regulate these two protein prenylation. The 2013 statistical 
update data from American Heart Association showed that 
adjusted population attributable fraction for cardiovascular 
disease mortality was 40.6% for high blood pressure [51]. 
Our data suggested that GGPPS was downregulated in the 
hearts after pressure overload and in failing human hearts. 
Cardiac-specific GGPPS knockout mice died around two 
months old owing to severe heart failure, characterized by 
cardiac fibrosis, apoptosis and decreased heart function. 
Further analysis indicated that GGPPS deletion in cardio-
myocytes led to the disrupted balance between protein far-
nesylation and geranylgeranylation. Increased Rheb farne-
sylation overactivated mTORC1 signaling and induced car-
diomyocyte hypertrophy. The persistent cardiomyocyte hy-
pertrophy caused the cardiac function to decrease with ag-
ing, which ultimately led to heart failure [52]. In conclusion, 
our data demonstrated that GGPPS played an indispensable 
role in postnatal heart function maintenance. The disrupted 
balance of protein prenylation by GGPPS ablation became a 
main cause for pathological heart remodeling (Figure 5). In 
the clinic, the inhibition of protein farnesylation or drugs 
that properly increase the level of geranylgeranylation pro-
vided new insight into pathologically hypertrophic heart 
diseases. 
4  Future directions 
GGPPS, a key enzyme for GGPP synthesis, can utilize FPP 
to produce GGPP. The geranylgeranylation of small G pro-
teins regulated by GGPPS promotes the protein-membrane 
interaction and transduces the downstream signaling path-  
 
 
Figure 5 (color online)  Disrupted protein prenylation balance regulates cardiomyocyte hypertrophy and chronic heart failure. GGPPS deficiency in cardi-
omyocytes disrupted the balance between protein farnesylation and geranylgeranylation. FPP accumulation increased Rheb farnesylation and then overac-
tivated mTORC1 signaling pathway, which induced cardiomyocyte hypertrophy. The persistent cardiomyocyte hypertrophy impaired cardiac function and 
induced pathological cardiac remodeling, which ultimately led to heart failure. 
334 Xu N, et al.   Sci China Life Sci   April (2015) Vol.58 No.4 
way. Disturbed GGPPS will lead to FPP accumulation and 
increase protein farnesylation, and thus activate the totally 
different signaling pathway. More than 100 proteins neces-
sary for eukaryotic cell growth and differentiation are ex-
perimentally proven to be posttranslationally modified by 
the covalent attachment of an isoprenoid lipid [53]. Howev-
er, 587 human genes encoding proteins provided from Uni-
Prot database possess a CXXX motif at their C-terminal end, 
which suggests that a large number of modified proteins 
need to be identified. Current technological methods to 
characterize protein prenylation are for the most part to 
study individual proteins. Therefore, to establish more so-
phisticated techniques that are capable of analyzing prenyl-
ation on a global scale towards the entire prenylome and 
uncover each concrete disease will be a great challenge in 
future research. 
Besides, GGPPS can precisely control all kinds of physi-
ological and pathological functions through interactions 
with other proteins. Growing evidence suggests that GGPP 
and FPP can directly bind to nuclear receptors (such as LXR, 
FXR, RXR) as a ligand to activate or suppress the role of 
transcriptional coactivators, and then regulate the expres-
sion of downstream proteins [54,55]. FPP was reported to 
promote osteoblast differentiation by enhancing FXR activ-
ity [56], while GGPP, as a LXR inhibitor, was involved in 
regulating cholesterol production and lipogenesis response 
to glucose concentration [57,58]. Taken together, GGPPS 
can affect the levels of GGPP and FPP, and may widely 
regulate the cellular physiology and pathology via a protein 
prenylation-independent pathway. 
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